What is the rating for RANI stock?

Rani Therapeutics Holdings, Inc. (RANI) has a "Avoid" rating based on our 6-factor quantitative model. It has a composite score of 33.1 and ranks #4293 out of 7,333 stocks in our coverage universe with a 1-star rating.

Is RANI a good stock to buy?

Based on our quantitative analysis, RANI receives a "Avoid" rating with 1 out of 5 stars. Key factors include: Quality score of 23.4, Value score of 32, and Momentum score of 42.1. The timing score is 46, indicating "Neutral" entry conditions. This is not investment advice - please conduct your own research.

What sector is RANI in?

Rani Therapeutics Holdings, Inc. (RANI) operates in the Manufacturing sector, specifically in the Pharmaceutical Products industry. It has a market capitalization of $0.04 billion.

What is RANI's P/E ratio?

P/E ratio data is not currently available for RANI.

Does RANI pay a dividend?

RANI does not currently pay a dividend.

What is RANI's market cap?

Rani Therapeutics Holdings, Inc. (RANI) has a market capitalization of $0.04 billion, making it a micro-cap stock.

What are the risks of investing in RANI?

Key risk factors for RANI include: higher volatility, notable short interest, and general market risk. As with all investments, there is risk of loss.

How does RANI compare to peers?

Within the Manufacturing sector, RANI ranks #4293 overall with a quality score of 23.4/100 and value score of 32/100.

What is RANI's revenue growth?

Revenue growth data is not currently available for RANI.

What is RANI's composite score?

Rani Therapeutics Holdings, Inc. (RANI) has a composite score of 33.1/100, which places it at rank #4293 out of 7,333 stocks. This score is derived from our proprietary 6-factor quantitative model that evaluates quality, value, momentum, investment efficiency, stability, and short interest.

How does RANI compare to the S&P 500?

RANI ranks in the top 41% of all stocks in our coverage universe with a composite score of 33.1. This places it below the market median.

What are the bull and bear cases for RANI?

Bull case: RANI scores highest in momentum at 42.1/100, indicating strong performance in this area. Bear case: The weakest factor is stability at 16.1/100, which may present a risk. Our overall assessment is Avoid with 1 out of 5 stars.

Is RANI overvalued or undervalued?

RANI appears overvalued based on our value factor score of 32/100.

What is RANI's momentum score?

RANI has a momentum score of 42.1/100, placing it in the moderate category.

When is RANI's next earnings date?

For the latest earnings date and analysis for RANI, visit our earnings calendar or check the RANI stock page for real-time updates. Our AI-generated earnings reports provide in-depth analysis after each quarterly report.

Is RANI a good stock to buy right now?

Based on our 6-factor quantitative model, Rani Therapeutics Holdings, Inc. (RANI) receives a "Avoid" rating with a composite score of 33.1/100. It is ranked #4293 out of 7,333 stocks. Key factor scores: Quality 23/100, Value 32/100, Momentum 42/100. The timing signal is "Neutral". This is quantitative analysis only — not investment advice.

What is the stock rating for RANI?

Rani Therapeutics Holdings, Inc. (RANI) has a "Avoid" rating and 1-star score. The composite score of 33.1 ranks it #4293 among 7,333 U.S. stocks. Ratings are updated weekly using academically-proven factor models.

What sector is RANI in?

Rani Therapeutics Holdings, Inc. operates in the Manufacturing sector (Pharmaceutical Products industry) with a market cap of $36 million. It is classified as a micro-cap stock.

Does RANI pay a dividend?

RANI does not currently pay a regular dividend. The company may be reinvesting profits for growth.

What is RANI's P/E ratio?

P/E ratio data is not currently available for RANI, which may indicate the company is not yet profitable.

How profitable is RANI?

RANI's quality factor score is 23/100. Margins are moderate to low, reflecting competitive market dynamics.

How is RANI valued compared to peers?

RANI's value factor score is 32/100 (higher = cheaper). Key multiples: . Trading at a premium relative to peers.

What is RANI's debt level?

Debt data is not available for RANI.

RANI has a beta of 2.02, meaning it amplifies market moves. Stability score: 16/100.

Does RANI have high short interest?

RANI's short interest factor score is 33/100 (higher = less short selling). Elevated short interest may indicate bearish sentiment or short squeeze potential.

RANI Stock Analysis — Rani Therapeutics Holdings, Inc. Price Target & Forecast 2026

IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.

HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.

RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.

RANI Stock Analysis — Rani Therapeutics Holdings, Inc. Price Target & Forecast 2026 | Blank Capital Research

Sector

Manufacturing

Industry

Pharmaceutical Products

Market Cap

$36M

Leadership

Talat Imran

Business Summary

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly. RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis, RT-102, a parathyroid hormone that is in preclinical studies for osteoporosis.

Operations

Headcount

110

Location

HQ Base

Pending Verification

Fundamental Spot Check

Context: 2025

Valuation

Market Cap

$36M

P/E Ratio

P/B Ratio

P/S Ratio

731.63xLagging

EV/EBITDA

Dividend Yield

0.00%

Efficiency & Risk

Gross Margin

Operating Margin

-6984.3%Lagging

ROE

Rev Growth (YoY)

Debt/Equity

Beta

2.02

Red = Sector Laggard

Black = Market Average

Revenue Breakdown

Strategic Timing Audit

WEAK

0/6

Negative Alignment — Extreme Caution

Quantitative Factor Convergence Analysis Verified

Momentum

42th pctl

Intelligence Feed

simplywall.stJan 31 Neutral

Insider Buyers At Rani Therapeutics Holdings Sitting On US$1.3m Profit

Insiders who purchased Rani Therapeutics Holdings, Inc. ( NASDAQ:RANI ) shares in the past 12 months are unlikely to be...

yahooJan 28 Positive

Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer

SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the promotion of Alireza Javadi, Ph.D., to Chief Technical Officer. “We are thrilled to announce Alireza’s promotion to Chief Technical Officer as we enter an exciting era for Rani, highlighted by our collaboration with Chugai and our newly initiated Phase

finance.yahoo.comJan 23 Neutral

Retail investors account for 65% of Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) ownership, while private equity firms account for 17%

Key Insights Rani Therapeutics Holdings' significant retail investors ownership suggests that the key decisions are...

BenzingaApr 17 Positive

Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Shares of The Travelers Companies, Inc. (NYSE: TRV) fell sharply during Wednesday’s session following first-quarter earnings. Travelers reported a mixed first quarter, with earnings lagging analyst' expectations. Core income per share reached $4.69 from $4.11 a year ago, missing the $4.90 consensus forecast. Net income per share rose to $4.80 from $4.13 a year earlier. Travelers shares dipped 8.1% to $205.03 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers INVO Bioscience, Inc. (NASDAQ: INVO) shares shot up 256% to $2.78 after the company reported a year-over-year increase in fourth-quarter revenue results and said it remains on track to reach its goal of reaching break-even or profitability within its current operations in 2024. Edible Garden AG Incorporated (NASDAQ: EDBL) gained 112% to $9.73 after the company reported preliminary first quarter FY24 results. Sintx Technologies, Inc. (NASDAQ: SINT) jumped 53% to $0.0350. VIA optronics AG (NYSE: VIAO) shares gained 50.4% to $0.3924 after dipping over 15% on Tuesday. AERWINS Technologies Inc. (NASDAQ: AWIN) jumped 42.2% to $4.70. The Children's Place, Inc. (NASDAQ: PLCE) climbed 35.5% to $9.64 after the company announced it entered into a new financing agreement with Mithaq Capital. Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) gained 32% to $5.38 after the company announced that it submitted three proposals since February to acquire all of the outstanding shares of common stock of Vanda Pharmaceuticals and confirmed that its most recent proposal to acquire Vanda remains open for Vanda and its Board of Directors to consider. EZGO Technologies Ltd. (NASDAQ: EZGO) gained 28% to $2.20. EZGO entered into a strategic cooperation framework agreement with Woteam to jointly explore the Southeast Asian Market. CXApp Inc. (NASDAQ: CXAI) shares rose 25% to $4.89 after the company announced 24% ARR growth in 2023. TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) rose 19.6% to $2.0461. WiSA Technologies, Inc. (NASDAQ:

BenzingaNov 9 Neutral

Analyst Ratings for Rani Therapeutics Hldgs

Rani Therapeutics Hldgs (NASDAQ:RANI) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 1 0 0 0 0 3M Ago 3 1 0 0 0 According to 6 analyst offering 12-month price targets in the last 3 months, Rani Therapeutics Hldgs has an average price target of $18.83 with a high of $20.00 and a low of $16.00. Below is a summary of how these 6 analysts rated Rani Therapeutics Hldgs over the past 3 ...Full story available on Benzinga.com

Earnings Call Transcripts

Unlock Valuation Tools

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Financial Intelligence Ledger

Verified SEC Filings Aggregate • RANI

Export

Metric Entity	10Y Historical Trend	2024	2023	2022	2021	2020
Revenue		$1M	$0	$0	$3M488.1%	$462K
Cost of Revenue	-	—	—	—	—	$0
Gross Profit	-	—	—	—	—	$462K
R&D Expense		$27M32.7%	$40M8.2%	$37M38.2%	$26M119.9%	$12M
Operating Expenses	-	—	—	—	—	$17M
Operating Income		-$53M19.3%	-$66M4.2%	-$63M23.0%	-$52M211.9%	-$17M
Interest Expense		$5M1.0%	$5M374.8%	$1M129.8%	$466K275.8%	$124K
Tax Provision		$0	$0	$70K70.7%	$41K17.1%	$35K
EBITDA		-$52M19.9%	-$65M3.8%	-$63M21.9%	-$52M222.1%	-$16M
Net Income		-$57M16.6%	-$68M7.2%	-$63M19.3%	-$53M217.8%	-$17M
EPS (Diluted)		$-1.0521.1%	$-1.333.9%	$-1.28	-	$0.00

SEC EDGAR Repository

Direct unfiltered access to 10-K, 10-Q and 8-K filings for RANI.

Open Regulatory Dossier

Data Integrity Notice

Figures adjusted for stock splits and restatements where applicable.

TTM (Trailing Twelve Months) data updates within 48 hours of quarterly filings.

Execution Benchmarks Audit

Operating Margin

Operating efficiency

-278359% SCTR

-6984.3%

Sector Avg: 2.5%

Dividend Yield

Direct cash return

-NaN% SCTR

0.0%

Sector Avg: 0.0%

Financial History

Forensic Accounting Audit

Watchlist

Margin Integritymedium RISK

High margin volatility — erratic forensic earnings quality

Algorithmic red flag detection based on regulatory SEC filings.

Unlock Financial Statements

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Shareholder Returns

Capital Allocation audit

Smart Money Conviction

Neutral

Synthesized from recent 13F filings, Form 4 insider transactions, and outstanding short interest metrics.

Governance Audit

Weak Index

WeakModerateStrong

Lower quality and stability scores may indicate governance concerns. Verified against factor-based integrity benchmarks.

Executive Operations

CEO: Talat Imran

Insider alignment Audit

No recent insider transactions available for RANI

Major Institutional Blocks

Top 5 Holders

Institutional cap table data requires verified 13F filing feeds.

Access SEC 13F Dossier →

Form 4 Filings

Recent Activity

Insider transaction data currently awaiting regulatory verification.

Access SEC Form 4 Dossier →

Regulatory Disclosure Vault

Proxy Statement (DEF 14A)

Exec Comp, Board Nominees, Proposals

Annual Report (10-K)

MD&A, Risk Factors, Strategy

Institutional Holders (13F)

Loading institutional data...

Insider Liquidity

Short Interest audit

SEC Risk Factors

Unlock Governance & Ownership

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Unlock Factor Analysis

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Unlock Investment Thesis

Get full access to institutional-quality research tools with Blank Capital Pro.

Upgrade to Pro

Starting at $19.99/mo

Institutional Peer Matrix

Top Manufacturing Universe

Stock	Rating	Score▼	Quality	Value	Momentum	P/E	EV/EBITDA	ROE	ROA	Gross Mgn	Op Mgn	Net Mgn	Rev Growth	Div Yield	D/E	Mkt Cap	AUDIT
$UL UNILEVER PLC		78	96	98	59	-	-	-	-	-	-	-	-	-	-	$0	VS
$ASML ASML HOLDING NV		77	89	86	83	-	-	-	-	-	-	-	-	-	-	$0	VS
$ESLT ELBIT SYSTEMS LTD		76	81	87	85	-	-	-	-	-	-	-	-	-	-	$0	VS
$MT ArcelorMittal		75	71	98	85	-	-	-	-	-	-	-	-	-	-	$0	VS
$AMAT APPLIED MATERIALS INC /DE		75	85	87	84	20.9x	13.6x	32.9%	20.5%	48.8%	30.6%	24.4%	7.7%	0.9%	32.0x	$148.6B	VS
$SIMO Silicon Motion Technology CORP		75	84	86	85	-	-	-	-	-	-	-	-	-	-	$0	VS
$CODA Coda Octopus Group, Inc.		74	83	90	79	16.3x	11.9x	7.4%	7.5%	68.3%	19.5%	18.2%	29.0%	0.0%	0.0x	$84M	VS
$GSK GSK plc		74	84	90	70	-	-	-	-	-	-	-	-	-	-	$0	VS
$EFXT Enerflex Ltd.		74	80	91	83	-	-	-	-	-	-	-	-	-	-	$0	VS
$BUD Anheuser-Busch InBev SA/NV		74	84	97	63	-	-	-	-	-	-	-	-	-	-	$0	VS
$RANI Rani Therapeutics Holdings, Inc.		33	23	32	42	-	-	-	-439.9%	-	-6984.3%	-7405.8%	-	0.0%	-	$36M
SECTOR BENCH	-	-	-	-	-	22.3x	11.5x	-1.9%	0.9%	44.1%	2.5%	1.0%	6.7%	0.0%	0.2x	-	REF

Access Full Manufacturing Intelligence Archive →

Lateral Comparison Mesh

$RANI / $UL AUDIT $RANI / $ASML AUDIT $RANI / $ESLT AUDIT $RANI / $MT AUDIT $RANI / $AMAT AUDIT

Market Intelligence FAQ

Rani Therapeutics Holdings, Inc. (RANI) receives a "Avoid" rating with a composite score of 33.1/100. It ranks #4293 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.

Full Research Publication

Equity Research Analysis: Rani Therapeutics Holdings, Inc. (RANI)

FEBRUARY 2026|Blank Capital Research Unit|Spot: $1.30

Price$1.30

Composite Score33.1/100

RatingAVOID (1★)

Rank#4293 OF 7,333

Market Cap$36M

Comments

Institutional Audit

Feb 25, 2026

Rani Therapeutics Holdings, Inc.

33.1

Executive Summary

Our quantitative model flags Rani Therapeutics Holdings, Inc. with an Avoid rating, assigning a composite score of 33.1/100 and 1 out of 5 stars. Ranked #4293 of 7,333 stocks, RANI falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.

Business Quality

Rani Therapeutics Holdings, Inc. registers a weak quality score of just 23/100, indicating significant profitability challenges. The company reports net margins of -7405.8% (sector avg: 1.0%). Low quality scores are often associated with businesses in turnaround mode, early-stage growth, or structurally challenged industries.

Intrinsic Valuation

With a value score of 32/100, RANI appears somewhat expensive relative to its fundamentals. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.

Capital Reinvestment

Rani Therapeutics Holdings, Inc.'s investment score of 25/100 suggests limited reinvestment activity. Key growth metrics include a return on assets of -439.9% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.

Market Momentum

RANI is currently showing below-average momentum at 42/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth data is not currently available, while a beta of 2.02 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.

Balance Sheet Health

Rani Therapeutics Holdings, Inc. registers a low stability score of 16/100, indicating high volatility and potentially stressed financial conditions. Key stability metrics include a beta of 2.02. Stocks at this level carry elevated capital loss risk and may be unsuitable for conservative portfolios without careful risk management.

Institutional Risk Profile

Rani Therapeutics Holdings, Inc.'s short interest score of 33/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include high market sensitivity (beta: 2.02), micro-cap liquidity risk. At $36M (micro-cap), RANI carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.

Sector Benchmark Analysis

Rani Therapeutics Holdings, Inc. is a micro-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #4293 of 7,333 overall (41st percentile). Key comparisons include operating margins of -6984.3% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.

Comparative Research Mesh

RANI VS S&P 500 (SPY)TOP MANUFACTURING PEERS

Strategic Alternatives

While RANI currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.

View Top Manufacturing Alpha →

RANI

Rani Therapeutics Holdings, Inc.

Business Summary

Operations

Location

Fundamental Spot Check

Valuation

Efficiency & Risk

Intelligence Feed

Insider Buyers At Rani Therapeutics Holdings Sitting On US$1.3m Profit

Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer

Retail investors account for 65% of Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) ownership, while private equity firms account for 17%

Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Analyst Ratings for Rani Therapeutics Hldgs

Unlock Valuation Tools

Unlock Financial Statements

Unlock Governance & Ownership

Unlock Factor Analysis

Unlock Investment Thesis

Lateral Comparison Mesh

Comments

SEC Risk Factors

Unlock Performance & Technicals

Economic Moat Audit

Economic Value Creation

Margin Superiority

Reinvestment Efficiency

Growth Durability

Financial Resilience

Uncertainty Audit

01Executive Summary

02Strategy & Outlook

Risk / Reward Variance

Research Verdict

Related Stocks

Executive Summary

Business Quality

Intrinsic Valuation

Capital Reinvestment

Market Momentum

Balance Sheet Health

Institutional Risk Profile

Sector Benchmark Analysis

Comparative Research Mesh

Strategic Alternatives

Factor Dispersion Audit

Sector Variance Findings

Intelligence Feed

Insider Buyers At Rani Therapeutics Holdings Sitting On US$1.3m Profit

Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer

Retail investors account for 65% of Rani Therapeutics Holdings, Inc.'s (NASDAQ:RANI) ownership, while private equity firms account for 17%

Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

Analyst Ratings for Rani Therapeutics Hldgs

Market Intel